Zai Lab announces China NMPA approval for Augtryo sNDA

Zai Lab (ZLAB) announced that China’s National Medical Products Administration has approved the supplemental new drug application, or sNDA, for Augtryo for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase gene fusion. The approval is intended for patients whose disease is locally advanced or metastatic, or where surgical resection is likely to result in morbidity, and who have either progressed following prior therapies or have no satisfactory alternative treatment options.